The Pharma Data

FEBRUARY 23, 2022

* Final analysis of the global VAT02 booster trial confirms universal ability to boost neutralizing antibodies 18- to 30-fold across vaccine platforms (mRNA, adenovirus). * efficacy against any symptomatic COVID-19 disease, in line with expected vaccine effectiveness in today’s environment dominated by variants of concern.

Vaccine 52

Vaccine Virus Trials Immune Response 52

The Pharma Data

AUGUST 16, 2021

Food and Drug Administration (FDA) to support the evaluation of a third, or booster, dose of the companies’ COVID-19 vaccine (BNT162b2) for future licensure. Vaccination is our most effective means of preventing COVID-19 infection – especially severe disease and hospitalization – and its profound impact on protecting lives is indisputable.

Vaccine 52

Vaccine FDA Virus Immune Response 52

The Pharma Data

JANUARY 15, 2021

15, 2021 (American Heart Association News) — Experts have a simple answer for heart and stroke patients questioning whether they need a COVID-19 vaccination. The Food and Drug Administration-approved vaccines pose no special problems for such patients, said Elkind, who also is president of the American Heart Association.

Vaccine 52

Vaccine Virus Immune Response Disease 52

The Pharma Data

JUNE 26, 2021

Sanofi and Translate Bio initiate Phase 1 clinical trial of mRNA influenza vaccine. The trial will evaluate the safety and immunogenicity of a monovalent flu vaccine candidate coding for the hemagglutinin protein of the A/H3N2 strain of the influenza virus. JUNE 22 , 2021.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

SEPTEMBER 5, 2021

million patients found no serious health effects that could be linked to the 2 mRNA COVID-19 vaccines. “The world is relying on safe and effective vaccines to bring an end to the COVID-19 pandemic. million for the first dose of either mRNA vaccine and 5.7 The total number of people evaluated was 6.2

Vaccine 52

Vaccine Clinical Trials Research Virus 52

The Pharma Data

JANUARY 14, 2021

14, 2021 — Folks who’ve gotten through a COVID-19 infection might naturally question whether they need to get a coronavirus vaccination when their turn comes. Twenty-five COVID patients were involved in the study, including nine with severe or moderate disease that required hospitalization. THURSDAY, Jan.

Vaccine 52

Vaccine Trials Virus Hospitals 52

The Pharma Data

AUGUST 24, 2020

China is set to move ahead with human testing of a potential coronavirus vaccine that has been created using insect cells. The National Medical Products Administration has granted approval to the West China Hospital of Sichuan University in Chengdu to begin a clinical trial. These were primarily border officials and health workers.

Vaccine 40

Vaccine Clinical Trials Packaging Regulations 40

The Pharma Data

JANUARY 13, 2021

13, 2021 — A single-shot COVID-19 vaccine from Johnson & Johnson has shown very strong results in early clinical trials, potentially providing a significant boost to U.S. vaccination efforts. Aaron Glatt, chair of the department of medicine and a hospital epidemiologist at Mount Sinai South Nassau Hospital in Oceanside, N.Y.

Vaccine 40

Vaccine Trials Clinical Trials Immune Response 40

The Pharma Data

OCTOBER 18, 2021

Northwestern Medicine scientists have shown for the first time that coronavirus vaccines and prior coronavirus infections can provide broad immunity against other, similar coronaviruses. The findings build a rationale for universal coronavirus vaccines that could prove useful in the face of future epidemics.

Vaccine 40

Vaccine Immune Response Virus Hospitals 40

The Pharma Data

SEPTEMBER 25, 2020

Johnson & Johnson Posts Interim Results from Phase 1/2a Clinical Trial of its Janssen COVID-19 Vaccine Candidate. Johnson & Johnson Posts Interim Results from Phase 1/2a Clinical Trial of its Janssen COVID-19 Vaccine Candidate. Immune responses were similar across the age groups studied, including older adults.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

NOVEMBER 17, 2020

Mymetics continues to progress its Covid-19 vaccine development plan based on its virosome-vaccine platform. The research at the University Hospital in Bern receives a boost through this funding and recognizes the work of our research teams.

Vaccine 40

Vaccine Hospitals Immune Response Clinical Trials 40

The Pharma Data

JUNE 1, 2022

has been appointed Senior Vice President and Head of the Company’s Vaccine Research & Development (R&D) organization effective August 1, succeeding Kathrin U. Anderson most recently served as Vice President and Chief Scientific Officer for Bacterial Research and Hospital within the Vaccine R&D organization.

Vaccine 40

Vaccine Research Laboratories Doctors 40

The Pharma Data

JANUARY 24, 2021

per cent of healthy Canadians had been exposed to SARS-CoV-2, the virus causing COVID-19. We have no choice but to keep up public health measures until vaccine-induced immunity grows substantially.”. As more Canadians are vaccinated, we will start seeing a significant increase in the proportion of the population with antibodies.

Vaccine 52

Vaccine Government Virus Hospitals 52

The Pharma Data

MARCH 3, 2022

The FDA decision is informed by the results of the Phase 2b proof-of-concept study of RSVpreF (NCT04032093), a global, double-blinded, placebo-controlled study that assessed the safety and immunogenicity of RSVpreF in healthy pregnant women ages 18 through 49 years old, who were vaccinated between 28- and 36-weeks gestation, and their infants.

Virus 52

Virus Vaccine Clinical Trials Trials 52

The Pharma Data

SEPTEMBER 17, 2020

The new Elecsys Anti-SARS-CoV-2 S test can quantitatively measure the level of antibodies against SARS-CoV-2 in patients who have been exposed to the virus. This is the focus of vaccines in development and convalescent plasma therapy. The test targets antibodies against the spike protein. said Thomas Schinecker, CEO Roche Diagnostics.

Vaccine 52

Vaccine Virus Clinical Trials Immune Response 52

The Pharma Data

AUGUST 9, 2021

Research by Lancaster University scientists to create a COVID-19 vaccine which can be administered through the nose has taken a significant step forward. The pre-clinical animal trials of the intranasal vaccine showed a reduction in both the impact of the disease itself and transmission of the virus.

Vaccine 52

Vaccine Virus Immune Response Disease 52

Eye on FDA

DECEMBER 10, 2020

Today the Food and Drug Administration will hold a meeting of the Vaccines and Related Biologics Advisory Committee (VRBAC) to consider the application for an Emergency Use Authorization (EUA) submitted by Pfizer/BioNTech for their investigative vaccine for COVID-19. After nearly 40 years, a vaccine still eludes us.

Vaccine 97

Vaccine FDA Virus Trials 97

The Pharma Data

JUNE 7, 2023

This is the first time an RSV vaccine for older adults has been granted European Marketing Authorisation. This authorisation for Arexvy means eligible adults can be vaccinated against RSV disease for the first time, reinforcing GSK’s long history of vaccine innovation. The vaccine was generally well tolerated.

Virus 40

Virus Vaccine Disease Trials 40

The Pharma Data

DECEMBER 12, 2020

Food and Drug Administration approved Pfizer’s coronavirus vaccine for emergency use on Friday, clearing the way for the launch of a national campaign to inoculate enough Americans to stem the spread of COVID-19. ” Who is first in line to be vaccinated? SATURDAY, Dec. 12, 2020 – The U.S.

Vaccine 52

Vaccine FDA Approval FDA Nurses 52

The Pharma Data

DECEMBER 14, 2020

14, 2020 — The Pfizer-BioNTech COVID-19 vaccine has received the first emergency use authorization (EUA) for a COVID-19 vaccine in the United States. The vaccine is administered in two doses three weeks apart. Researchers found the vaccine was 95 percent effective in preventing COVID-19. MONDAY, Dec. Redfield, M.D.,

Vaccine 52

Vaccine Nurses FDA Virus 52

The Pharma Data

MARCH 25, 2021

European Medicines Agency to Conduct First-Ever Parallel Assessment of a Medicinal Product, Takeda’s Dengue Vaccine Candidate (TAK-003), for use in the EU; Countries Outside of the EU through the EU-M4all (Previously Article 58) Procedure. About TAK-003. 4,5 Efficacy varied by serotype.

Vaccine 52

Vaccine Virus Trials Hospitals 52

The Pharma Data

DECEMBER 16, 2020

Food and Drug Administration (FDA) advisory panel in regard to the COVID-19 vaccine from Moderna. The Vaccines and Related Biological Products Advisory Committee will be determining whether the product should be authorized for emergency use, according to CNBC. The vote itself is not slated to take place until after 3 p.m.

Vaccine 52

Vaccine Immune Response FDA FDA Approval 52

The Pharma Data

JANUARY 16, 2021

16, 2021 — President-elect Joe Biden described an ambitious national vaccination plan on Friday that will deliver coronavirus vaccines to far more people and invoke a wartime law to boost vaccine production. Even if Biden invokes the Korean War-era Defense Production Act, it may take some time to ease vaccine shortages.

Vaccine 52

Vaccine Nurses Virus Hospitals 52

The Pharma Data

NOVEMBER 10, 2021

Next generation vaccines for COVID-19 should aim to induce an immune response against ‘replication proteins’, essential for the very earliest stages of the viral cycle, concludes new research carried out by UCL scientists. ” Discovering the T cell response to replication proteins. .”

Vaccine 52

Vaccine Immune Response Virus International 52

The Pharma Data

SEPTEMBER 30, 2021

As one among the leading global vaccines companies, we still bring options which help protect people’s health round the world,” said Michael Greenberg, MD, MPH, Medical Head, Sanofi Pasteur North America. “We A study conducted from 2014 to 2015 showed 72% of infants hospitalized for RSV were previously healthy with no underlying conditions.3.

Vaccine 52

Vaccine Research Virus Disease 52

The Pharma Data

DECEMBER 11, 2020

70 Percent Efficacy Found for Oxford COVID-19 Vaccine. 11, 2020 — The ChAdOx1 nCoV-19 vaccine has an overall efficacy of 70.4 Participants in the vaccine group received two doses containing 5 x 10 10 virus particles (standard dose; SD/SD cohort); a subset in the U.K. Professional. FRIDAY, Dec. 8 in The Lancet.

Vaccine 52

Vaccine Pharmaceutical Companies Virus Trials 52

The Pharma Data

MARCH 11, 2021

(NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced real-world evidence demonstrating dramatically lower incidence rates of COVID-19 disease in individuals fully vaccinated with the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2), underscoring the observed substantial public health impact of Israel’s nationwide immunization program.

Vaccine 52

Vaccine Clinical Trials Hospitals Licensing 52

The Pharma Data

MARCH 29, 2022

Food and Drug Administration authorized a second booster dose of either the Pfizer-BioNTech or the Moderna COVID-19 vaccines for older people and certain immunocompromised individuals. The FDA previously authorized a single booster dose for certain immunocompromised individuals following completion of a three-dose primary vaccination series.

Vaccine 52

Vaccine FDA FDA Approval Immune Response 52

The Pharma Data

JANUARY 12, 2021

Doses are being supplied for use pursuant to the FDA Emergency Use Authorization for high-risk patients with mild to moderate COVID-19 in order to reduce the risk of progression to severe COVID-19 and/or hospitalization. “Tackling the COVID-19 pandemic will require a combination of public health measures, vaccines and therapeutics.

Government 52

Government Hospitals Virus Clinical Trials 52

The Pharma Data

DECEMBER 8, 2020

The COVID-19 vaccine under development by China’s Sinopharm is showing efficacy of 86%, health authorities from the United Arab Emirates reported this morning. In August, the company reported the vaccine candidate triggered antibody-based immune responses in early and mid-stage trials. Source link.

Vaccine 52

Vaccine Immune Response Virus Clinical Trials 52

The Pharma Data

DECEMBER 18, 2020

Food and Drug Administration issued an emergency use authorization (EUA) for the second vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The emergency use authorization allows the Moderna COVID-19 Vaccine to be distributed in the U.S. Hahn , M.D.

Vaccine 52

Vaccine FDA Clinical Trials FDA Approval 52

The Pharma Data

MAY 16, 2022

The profound health and economic impact of the Pfizer-BioNTech vaccine during its first year of rollout in the US is described in detail in a new study in the peer-reviewed Journal of Medical Economics. It is estimated that in 2021 the vaccine, the most widely used against COVID-19 in the US, prevented 8.7

Vaccine 52

Vaccine Hospitals Virus Disease 52

The Pharma Data

JANUARY 13, 2021

patients hospitalized with COVID-19. We are pleased vaccines are now approved for the prevention of COVID-19; however, a significant unmet need remains for effective treatments for symptomatic patients. Patient Population: 45 hospitalized patients with COVID-19. LONDON and RALEIGH, N.C., David Zaccardelli, Pharm.

Hospitals 52

Hospitals Clinical Trials Therapies Treatment 52

The Pharma Data

DECEMBER 2, 2020

The License provides EYAM with the exclusive right to develop several proprietary COVID-19 vaccine candidates in a self-amplifying mRNA vaccine platform. EYAM anticipates rapid commencement of animal trials for these COVID-19 vaccine candidates. This License Agreement represents an important corporate milestone.

Licensing 52

Licensing Licensing Vaccine Virus 52

The Pharma Data

SEPTEMBER 18, 2020

This week Pharma IQ looks at how the pharma industry is expanding its vaccine manufacturing and testing protocols to ensure the deadly Covid-19 outbreak yields in its spread around the globe. . BioNTech acquires Novartis GMP manufacturing site to expand Covid-19 vaccine production.

Vaccine 52

Vaccine Long-Term Care Facilities Clinical Supply Laboratories 52

The Pharma Data

NOVEMBER 24, 2020

24, 2020 – At least thee new COVID-19 vaccine candidates are already in the pipeline, will a roll-out expected early in the new year. “These are immune responses, so if you feel something after vaccination, you should expect to feel that. . Vaccines work to fight disease by producing an immune response within the body.

Vaccine 52

Vaccine Virus Immune Response Hospitals 52

The Pharma Data

DECEMBER 10, 2020

Food and Drug Administration advisory panel will vote on Thursday whether to recommend emergency approval of Pfizer’s coronavirus vaccine, a decision that will come not a moment too soon as the country reported more than 3,000 new COVID-19 deaths on Wednesday. Meanwhile, U.S.

Vaccine 52

Vaccine FDA Hospitals Doctors 52